Illumina will seek to cut $100 million in expenses by the end of this fiscal year as it plans to deal with a loss of revenue ...

Amid increasing economic tensions with the United States, China recently announced that it would ban Illumina, a U.S.-based company and the ...

The San Diego company also lowered its financial guidance for 2025 in response to China’s import restrictions.

The stock's rise snapped a four-day losing streak.

Additionally, Illumina — alongside the rest of the biotech industry — is facing uncertainty amidst looming cuts to research funding and grants, primarily from the National Institutes of Health ...

Illumina slashes costs by $100 million after China bans its sequencers. The company lowers its 2025 EPS outlook and aims for ...

In a report released yesterday, Conor McNamara from RBC Capital maintained a Buy rating on Illumina (ILMN – Research Report), with a price ...

China’s Ministry of Commerce said it would ban Illumina, a San Diego company, from importing its gene-mapping products in China. Illumina is the world’s leading producer of gene-sequencing ...

Illumina has been barred from exporting its DNA sequencers to China, which closed its doors to the company in response to the Trump administration expanding its tariffs on the country. Previously ...

China has announced a ban on the import of genetic sequencers from the U.S. medical equipment maker Illumina. This decision ...

RBC Capital lowered the firm’s price target on Illumina (ILMN) to $128 from $247 but keeps an Outperform rating on the shares. The company’s ...

But for biotech firm Illumina, a leading maker of gene-sequencing equipment, it has been a barrage of bad news. The company was already grappling with fierce competition and slowing growth ...